of intercellular communication, microparticles could be a novel link between activated cellular compartments in the pathogenesis of SSc.
Introduction
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology, which affects the skin and various internal organs. SSc is characterized by an activation of immune cells, peripheral vasculopathy, the occurrence of autoantibodies, and tissue fibrosis. The clinical manifestations of SSc are the result of a complex interaction of a variety of different cell types. Endothelial cell damage with apoptosis resulting in the loss of capillaries is considered as one of the earliest changes in the pathogenesis of the disease (1) . There are also inadequate attempts to compensate for the reduced capillary density leading to the formation of tortuous, bushy and giant capillaries (2) . Activation of the immune system with the formation of perivascular infiltrates is another early feature of SSc. These infiltrates are dominated by T cells and are thought to contribute to the activation of fibroblasts by the release of profibrotic cytokines such as IL-4 (3).
Microparticles are a heterogeneous population of small, membrane-coated vesicles. They are released from a variety of cells during activation and apoptosis via an exocytic budding process. Long considered as inert debris, microparticles are now appreciated as important mediators of cellular crosstalk (4) . Microparticles expose an array of antigens from their parental cells on their surface that can be used to identify the cell types from which they originate. Microparticles regulate inflammation, stimulate coagulation, affect vascular functions and have also been implicated in apoptosis and cell proliferation (4) . Interestingly, increased numbers of microparticles are found in systemic inflammatory conditions such as sepsis (5) and multiple sclerosis (6) . Recently, microparticles have also been suggested as markers of endothelial cell damage in vasculitis and acute coronary syndromes (5, 7).
Since both inflammation and endothelial cell damage are hallmarks of SSc, we speculated that the number of microparticles might be elevated in SSc. To test this hypothesis, microparticles derived from different cell types were isolated from the plasma of patients with diffuse and limited SSc, and the microparticle count was compared to that of healthy individuals. In addition, we searched for associations of microparticles with major clinical manifestations of SSc. Results of these studies indicate that levels of microparticles are elevated in the blood of patients with SSc.
The inverse correlation with skin fibrosis suggests that microparticles may attenuate fibrotic disease manifestations.
Material and methods

Patients
Thirty-seven consecutive, unselected patients with SSc were recruited at the Department of Rheumatology of the University of Florence. All patients fulfilled the American College of Rheumatology criteria for SSc (8) . There were 33 women and 4 men with a median age of 63 years (range 29-82 years). Patients with overlap syndromes/mixed connective tissue disease and other connective tissue diseases were excluded from the study.
Healthy volunteers (n = 15) were used as controls. The control group consisted of 12 women and 3 men with a median age of 55 years (range 42-70 years). All patients and controls were of Caucasian origin. All patients signed a consent form approved by the ethical committee.
Clinical assessment
An extensive clinical profile was established for each SSc patient. Patients' characteristics are summarized in Table 1 . SSc patients were classified as limited or diffuse SSc according to the criteria proposed by LeRoy et al. (9) . The presence of fingertip ulcers at the time of blood drawing, other skin ulcers ("cutaneous ulcers", e.g. at the lower extremities, elbows, forearms), teleangiectasias and disease duration since first non Raynaud symptoms were recorded. All patients reported the occurrence of Raynaud's phenomenon after exposure to low temperatures. The modified Rodnan skin score was assessed by the same experienced rheumatologist in all patients at 17 body areas by clinical palpation and was rated 0-3, with a maximum total score of 51. Disease activity was measured according to Valentini et al (10) .
Nailfold videocapillaroscopy was performed in a blinded manner for the analysis of microvascular abnormalities. Patients were allowed to adapt to room temperature (20-22°C) for at least 15 min before the examination was started. The nailfolds of all 10 fingers were analyzed for the following parameters: presence of enlarged and giant capillaries, pericapillary edema, hemorrhages, loss of capillaries, ramified/bushy capillaries and disorganization of the vascular distribution. According to these features, patients were grouped into capillaroscopy changes with an early, active and late pattern using the criteria proposed by Cutolo et al. (11) . The early pattern included the criteria of few giant capillaries and capillary hemorrhages, relatively well preserved capillary distribution and no evident loss of capillaries. The criteria for the active pattern were frequent capillary hemorrhages and giant capillaries, moderate loss of capillaries with some avascular areas, mild disorganization of the capillary architecture and absent or some ramified capillaries.
Finally, the late pattern criteria were irregular enlargement of capillaries, few or absent giant capillaries, absence of hemorrhages, severe loss of capillaries with large avascular areas, severe disorganization of the normal capillary distribution and frequent ramified/ bushy capillaries. It should be noted that these criteria are frequently used, but that some aspects of this classification are not yet validated.
Pulmonary involvement was examined by the carbon monoxide diffusion capacity using the single-breath method standardized for hemoglobin. Antinuclear antibodies were determined by ELISA, anti-centromere antibodies determined on Hep-2 cells and anti-topoisomerase I (Scl-70) antibodies were determined by immunoblot analysis. Plasma levels of VEGF were measured using a commercially available ELISA (R&D Systems, Minneapolis, USA) as described (12) . Concomitant treatment of SSc patients included angiotensin-converting enzyme inhibitors, calcium channel blockers, proton-pump inhibitors, clebopride and topical glyceryl trinitrate. All patients had received therapy with intravenous prostanoids (alprostadil and iloprost).
Blood for this study was drawn after a wash-out period of at least 30 days after the last prostanoid infusion. None of the study patients received corticosteroids, methotrexate, cyclophosphamide, D-penicillamine or other potentially diseasemodifying drugs.
Isolation of microparticles by differential centrifugation
Blood was obtained using a 19 gauge needle and collected into citrated tubes.
Immediately after blood drawing, plasma was centrifuged at 1500 g for 10 min, supernatant was collected and divided into aliquots. Aliquots were stored in liquid nitrogen till used for the analysis.
The method for the isolation of microparticles by differential centrifugation has been established previously for various cell types (4) . Four milliliters of plasma were centrifuged at 1500 g for 5 min to remove suspended cells. Afterwards, the cell-free supernatants were centrifuged at 100000 g for 20 min using a Centrikon T-1065 centrifuge with a TST28.38 head (Kotron Instruments, Munich, Germany) and 16 x 76 mm centrifugation tubes (Beckman instruments, Fullerton, CA, USA). The supernatant was removed and the pellet was washed twice with 10 ml apop buffer (5 mM KCl, 1 mM MgCl 2 and 136 mM NaCl, pH 7.4). The microparticles were then quantified and characterized by flow cytometry.
Labeling of microparticles and flow cytometry analysis (FACS)
For the differentiation and quantification of microparticles derived from platelets, erythrocytes, granulocytes, monocytes, T cells, B cells and endothelial cells by FACS, microparticles were resuspended in apop buffer containing 2.5 mM CaCl 2 and 1 % microparticle-free FCS to a final volume of 500 µl as described recently (4, 
Statistical analysis
Statistical analysis was performed by the biostatistician of the group (DH).
Data are expressed as mean ± standard error of the mean, if not indicated otherwise.
Differences in microparticle counts were tested between groups composed by categorical parameters to assess association of these disease parameters with microparticle counts. Thereby, the Kruskal-Wallis test was used for analysis of more than two groups, and the Mann Whitney U-test for analysis of two groups. To assess correlation of continuous variables with microparticle counts, Spearman's rank correlation coefficients were calculated. P-values < 0.05 were considered statistically significant.
Multivariate linear regression models were applied in a stepwise forward and stepwise backward manner to determine an optimal combination of variables predicting the microparticle count. Since case numbers were low relative to the parameters to examine, an inclusion criteria of p ≤ 0.1 was used in the stepwise forward procedure . In the stepwise backward procedure, an inclusion criteria of p ≤ 0.05 was applied. The model was calculated including a constant term.
Results
Cellular origin of microparticles in the blood of SSc patients and controls
The origin of microparticles in the peripheral blood was identified by staining of microparticles with cell-type specific surface markers. In the blood of patients with SSc and healthy donors, platelets were the most common source of microparticles.
The percentage of CD42 positive microparticles was 66.9 ± 5.2% in patients with SSc and 70.2 ± 3.9% in healthy donors (see absolute numbers below). Endothelial cells were the second most common source of microparticles with CD144 positive microparticles accounting for 8.8 ± 0.9 (SSc) and 7.6 ± 1.2% (healthy donors) of the total microparticles in the blood. Lower percentages of less than 5% were found for microparticles from other cellular origin such as erythrocytes, granulocytes, monocytes, T cells and B cells.
Increased numbers of microparticles in the blood of SSc patients
Since platelet and endothelial cell microparticles were the most common source of microparticles in the blood, and since T cells and monocytes have been implicated in the pathogenesis of SSc, these microparticles were selected for further analysis. The absolute number of microparticles of total, platelet, endothelial cell, T cell and monocytes origin in patients with SSc and healthy controls are summarized in Figures 1A-1E .
Patients with SSc showed 88.0 ± 4.8 x 10 5 microparticles/ml plasma. This total number of microparticles was strongly increased compared to the values that were found in the plasma of healthy controls (42.3 ± 9.4 x 10 5 microparticles/ml plasma; p < 0.001, Figure 1A ). Elevated total numbers of microparticles per milliliter plasma were found in both patients with limited and diffuse systemic sclerosis (87.6 ± 4.5 x 5 microparticles/ml plasma respectively, each p < 0.05 compared to healthy controls, Figure 1A ).
Along with the higher total number of microparticles, the number of microparticles derived from platelets was significantly increased in patients with systemic sclerosis. There were 58.8 ± 4.0 Figures 1D and 1E ). The number of T cell and monocytes-derived microparticles was significantly elevated in both patients with limited and diffuse SSc without differences between these subgroups.
Notably, there was no difference in the platelet, erythrocyte, monocytes and T cell counts between SSc patients and controls, indicating that the increased number of microparticles was not simply caused by increased cell numbers.
Concomitant diseases do not contribute to the increased number of microparticles in SSc patients
Since vascular diseases such as coronary artery disease and thrombotic diseases such as the antiphospholipid antibody syndrome are associated with increased numbers of microparticles (13, 14) , we next searched for confounding clinical parameters that could have influenced the results. Arterial hypertension was found in 4/37 patients with SSc (11%), and in none of the controls. All other established risk factors for atherosclerosis such as smoking, diabetes, hypercholesterolemia and hyperlipidemia were equally distributed between patients and controls (Table 1 ).
In addition, all patients with known coronary heart disease and clinical manifestations of atherosclerosis such as stroke or peripheral obliterative arterial disease were excluded from our study.
Similarly, there was no evidence for thrombotic diseases in the past medical history of patients and controls. Increased levels of antiphospholipid-antibodies were not detectable in patients and controls (Table 1) .
Moreover, patients and controls with systemic infections, which are also associated with increased numbers of microparticles, were not included in the study.
Taken together, these data indicate that the increased numbers of microparticles were not caused by confounding vascular, infectious or thrombotic diseases in our patient population.
Correlation of microparticles with clinical manifestations of SSc
The increased number of microparticles from endothelial cells, inflammatory cells and platelets likely reflects their cellular activation in the pathogenesis of SSc (4) . Based on these findings, we hypothesized that the number of microparticles could be associated with clinical vascular and fibrotic manifestations of the disease.
In fact, in univariate analysis, the number of total microparticles correlated significantly with the modified Rodnan Skin Score (p < 0.05, r = -0.333). As shown in in that they allow membrane interactions between cells at long distances (15) . The present study is the first report that the levels of microparticles are elevated in the blood of patients with SSc, suggesting that this novel mechanism of intercellular interaction can contribute to disease pathogenesis.
Increased levels of microparticles have been detected in diseases with vascular damage such as atherosclerosis and coronary artery disease (7, 14, (16) (17) (18) .
To avoid confounding effects related to differences in the prevalence of these diseases, all patients with clinical evidence of coronary artery disease were excluded from the study. In addition, established risk factors for atherosclerosis such as smoking, diabetes, hypercholesterolemia and hyperlipidemia were not present in both SSc patients and controls (except one SSc patient with diabetes). Patients suffering from other diseases known to increase the numbers of microparticles in the blood such as infectious diseases (5, 19) , vasculitis and antiphospholipid syndrome (7, 13) were excluded from the study. Thus, the increased number of microparticles in the blood of SSc patients is not a secondary phenomenon due to comorbidities, but rather reflects the disease process in SSc itself.
In this regard, the release of microparticles from their parental cells is known to be enhanced in activated cells, e.g. by stimulation with cytokines (4). In fact, Disease subsets
• limited and diffuse SSc compared to healthy individuals (p < 0.05, Figure 1A) . Similarly, the number of microparticles derived from platelets (p < 0.05, Figure 1B ), endothelial cells (p < 0.05, Figure 1C) , monocytes (p < 0.05, Figure 1D) , and T cells (p < 0.05, modified Rodnan skin score of <10/51 compared to patients with a modified Rodnan skin score of ≥10/51. In addition, the total number of microparticles were significantly lower in patients with cutaneous ulcers (e.g. at the lower extremities, elbows, forearms, Figure 2C ) compared to patients without ulcers. Box plots with 25% percentiles and medians. # indicates significance at p < 0.05.
